ResMed (NYSE: RMD) revenue
ResMed reported revenue of $5,653m for fiscal 2026, 9.9% more than in fiscal 2025 ($5,146m). Since fiscal 2017 its revenue has grown by 173.5%, an average growth of 11.8% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2026 | $5,653m | +9.9% | $1,887m | 33.4% |
| 2025 | $5,146m | +9.8% | $1,685m | 32.7% |
| 2024 | $4,685m | +10.9% | $1,320m | 28.2% |
| 2023 | $4,223m | +18.0% | $1,132m | 26.8% |
| 2022 | $3,578m | +11.9% | $1,000m | 28.0% |
| 2021 | $3,197m | +8.1% | $903.7m | 28.3% |
| 2020 | $2,957m | +13.4% | $809.7m | 27.4% |
| 2019 | $2,607m | +11.4% | $579.3m | 22.2% |
| 2018 | $2,340m | +13.2% | $541.8m | 23.2% |
| 2017 | $2,067m | — | $425.8m | 20.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of ResMed
- How much revenue did ResMed make in fiscal 2026?
- ResMed reported revenue of $5,653m for fiscal 2026, compared with $5,146m in fiscal 2025.
- How much has the revenue of ResMed grown?
- Between fiscal 2017 and fiscal 2026 it went from $2,067m to $5,653m: 173.5% more, an average growth of 11.8% a year.
- What was the best year for revenue at ResMed?
- Of its last 10 fiscal years, fiscal 2026, with $5,653m.
- Where do the figures for ResMed come from?
- From the annual report (Form 10-K) that ResMed files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ResMed files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on ResMed: the ResMed page · annual accounts · net income · dividends paid · insider transactions.
Dividend per share of ResMed by fiscal year, with the filing behind every figure: ResMed dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.